Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Japan's First New-Type Influenza Vaccines Recommended for Approval
September 17, 2007
-
ARCHIVE SURVEY/Antirheumatic Drug Market Grew by 49% in 2006: Fuji Keizai Databook
September 17, 2007
-
ARCHIVE Takeshi Erikawa Appointed
September 10, 2007
-
ARCHIVE Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
-
ARCHIVE Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
-
ARCHIVE Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
-
ARCHIVE Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
-
ARCHIVE R&D NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Korosho to Create "Healthcare Clusters" to Promote Drug Discovery
September 10, 2007
-
ARCHIVE Our Generics Had Economic Effects of \58.6 Bil. in 2006: Taiyo Yakuhin
September 10, 2007
-
ARCHIVE JMA Proposes Same Prices for Original Drugs and Generics
September 10, 2007
-
ARCHIVE Major Pharmas Tie Up with Generic Firms: Seminar
September 10, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 10, 2007
-
ARCHIVE JGPRG to Designate Oct. as "Generic Drug Promotion Month"
September 10, 2007
-
ARCHIVE NBI to Go on Offensive in the Market for ARBs with 1,000 MRs
September 10, 2007
-
ARCHIVE GENERICS NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Leiden Bio Science Park Is Ideal Gateway to Europe: F. van As of Leiden City
September 10, 2007
-
ARCHIVE Reimbursement Begins for 4 Lab Tests
September 10, 2007
-
ARCHIVE Korosho Asks Makers to Present Criteria for Allowances ASAP after Notification of New NHI Prices
September 10, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 10, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…